This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Mallinckrodt (MNK) Up on Earnings and Revenues Beat in Q4
by Zacks Equity Research
Mallinckrodt (MNK) shares gained as the company beat both earnings and revenue estimates in the fourth quarter as Inomax sales revived somewhat.
Perrigo (PRGO) Postpones Q4 Earnings Results, Shares Down
by Zacks Equity Research
Perrigo (PRGO) to reschedule fourth-quarter 2017 and full-year earnings results. However, the company releases preliminary unaudited numbers for the full year.
Endocyte (ECYT) Reports Wider-Than-Estimated Loss in Q4
by Zacks Equity Research
Endocyte, Inc. (ECYT) posts wider-than-expected loss in the fourth quarter of 2017. The company finalized a phase III VISION trial design for 177Lu-PSMA-617 following a successful End of Phase II meeting with the FDA.
Is a Beat in Store for Adverum (ADVM) This Earnings Season?
by Zacks Equity Research
Adverum Biotechnologies (ADVM) will report its fourth-quarter results in early March. Investors focus is expected to be on pipeline updates.
BioMarin (BMRN) Q4 Loss Wider Than Expected, Sales Beat
by Zacks Equity Research
BioMarin (BMRN) reports wider-than-expected loss in the fourth quarter of 2017 but beat estimates for sales on higher product revenues.
Corcept's (CORT) Earnings and Sales Meet Estimates in Q4
by Zacks Equity Research
Corcept (CORT) reports in-line results for the fourth quarter of 2017 and also announces top-line interim phase II data for its pipeline candidate relacorilant.
Novavax (NVAX) in Focus: Stock Moves 8.3% Higher
by Zacks Equity Research
The shares of Novavax (NVAX) rose over 8% yesterday.
The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal
Top Research Reports for Novo Nordisk, TJX Companies & Cigna
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk (NVO), TJX Companies (TJX) and Cigna (CI).
Regeneron (REGN) Q4 Earnings & Revenues Top, Eylea Sales Grow
by Zacks Equity Research
Regeneron (REGN) fourth-quarter results were encouraging as the company topped both earnings and sales estimates on the back of Eylea sales.
Regeneron (REGN) Tops Q4 Earnings & Sales
by Ekta Bagri
Regeneron???s fourth-quarter 2017 earnings (excluding one-time charges) and sales topped expectations.
Sanofi (SNY) Q4 Earnings Lag on Weak Diabetes/Vaccines Sales
by Zacks Equity Research
Sanofi misses estimates for both earnings and sales in the fourth quarter hurt by continued weakness in the Diabetes franchise and lower vaccine sales. Sanofi looks to return to growth in 2018.
REGN vs. ALXN: Which Stock is Poised for Better Q4 Earnings?
by Zacks Equity Research
Let's take a look at which of these biotech companies, Alexion (ALXN) or Regeneron (REGN) has an edge ahead of their Q4 release.
Will Regeneron (REGN) Disappoint Investors in Q4 Earnings?
by Zacks Equity Research
With a mixed track record, we expect investor focus on Regeneron's (REGN) Eylea sales and uptake of Dupixent when it reports Q4 results.
Vertex (VRTX) & Other Drug Stocks with FDA Catalysts this February
by Arpita Dutt
Here is a look at Vertex (VRTX) and a few other companies that await a decision from the FDA in February for label expansions or new drugs.
Regeneron's Dupixent Receives MHLW Nod for Label Expansion
by Zacks Equity Research
Ministry of Health, Labor and Welfare (MHLW) in Japan has granted approval for the label expansion of Regeneron's (REGN) Dupixent.
Ophthotech Begins Phase II Zimura Study in Stargardt Disease
by Zacks Equity Research
Ophthotech (OPHT) is focusing on Zimura following the failure of the Fovista studies.
Can Biotech Keep Last Year's Momentum Alive in 2018?
by Zacks Equity Research
The biotech sector performed impressively in 2017 and the momentum is expected to continue in 2018 driven by new drug approvals. Acquisitions will also remain in focus.
Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus
by Arpita Dutt
Focus this week was on preliminary results and 2018 outlooks provided by several companies including Celgene (CELG) at a healthcare conference.
AbbVie's Upadacitinib Gains Breakthrough Therapy Designation
by Zacks Equity Research
AbbVie's (ABBV) atopic dermatitis (eczema) candidate, upadacitinib, gets breakthrough therapy status from the FDA.
Regeneron, Sanofi Expand Investment in Cemiplimab & Dupilumab
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi announced that they will expand their investment for the development cemiplimab in oncology, and label expansion of dupilumab in Type II allergic diseases.
Momenta & Mylan to Initiate Trial on Biosimilar of Eylea
by Zacks Equity Research
Momenta (MNTA), in collaboration with Mylan (MYL), plans to initiate a trial of M710, a proposed biosimilar of leading ophthalmology drug Eylea, in the first half of 2018.
Biotech Stock Roundup: Label Expansion for Exelixis's Cabometyx, FDA Nod for Spark's Gene Therapy
by Arpita Dutt
A one-time gene therapy for an inherited retinal disease gained FDA approval this week while Exelixis's (EXEL) Cabometyx can now be used in treatment-naive advanced renal cell carcinoma patients.
Regeneron in Strategic Immuno-Oncology Collaboration With ISA
by Zacks Equity Research
Regeneron Pharmaceuticals (REGN) and ISA Pharmaceuticals inked an agreement to advance ISA101 in combination with cemiplimab.
The Zacks Analyst Blog Highlights: Disney, Kraft Heinz, Caterpillar, Humana and Regeneron
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Disney, Kraft Heinz, Caterpillar, Humana and Regeneron